4. Treatment of HCV genotypes 1 and 4 infection
Duration of treatment: 48 weeks.
Therapeutic options
Peginterferon α-2a 180 μg per week subcutaneously + Ribavirin according to body mass (≤ 75 kg: 1,000 mg per day; < 75 kg but ≤ 90 kg: 1,200 mg per day; < 90 kg: 1,400 mg per day).15
or
Peginterferon α-2b 1.5 μg/kg per week subcutaneously + Ribavirin according to body mass (< 65 kg: 800 mg per day; ≥ 65 kg but ≤ 85 kg: 1,000 mg per day; < 85 kg but ≤ 105 kg:
1,200 mg per day; < 105 kg: 1,400 mg per day).14,24
Treatment may be discontinued
- In patients who do not achieve at least a pEVR
- In patients who achieve a pEVR but are still HCV RNA positive at week 24.
In patients in whom viral clearance is delayed (HCV RNA becomes negative between weeks 12 and 24), consideration should be given to extending therapy to 72 weeks.25,26
Patients in whom treatment is continued through 48 to 72 weeks and whose HCV RNA is negative at end of treatment should be retested for HCV RNA 24 weeks later to establish whether an SVR has been achieved.